SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.235+0.5%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Haolin Ni who wrote (534)1/18/2000 1:07:00 PM
From: John Finley  Read Replies (1) of 645
 
I mean it is difficult to develop the live attenuated vaccine when the viral antigen, like flu virus, is changing

Yes, this is why AVIR plans to check with the CDC at the start of every season to anticipate which strains will be prevalent and then manufacture the appropriate vaccine. However, having the precise strain isn't necessary. In the efficacy studies it is pointed out that Flumist is effective (at a reduced level) on other strains.

JF
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News